Most-enhancing tumor volume by MRI radiomics predicts recurrence-free survival "early on" in neoadjuvant treatment of breast cancer.

While using the highest quartile cut-point for FTV at the early treatment time-point the log-rank test yielded a statistically significant difference only for the triple-negative subgroup [ 8 ], performing the same analysis for METV yielded statistically significant differences for the hormone-receptor positive/HER2 negative, and HER2 positive subgroups while the difference for the triple negative subgroup failed to reach statistical significance (Fig. 4 ).

also in 6,035 other papers